Abstracts tagged "giant cell arteritis"

Abstract Number: 1882 • ACR Convergence 2021
Clinical Characteristics and Reliability of a Self-Reported Diagnosis of Large-Vessel Vasculitis
Tannaz Kermani¹, Jason Springer², Dianne Shaw³, Kalen Young⁴, Cristina Burroughs⁵ and Peter Merkel⁶, ¹University of California Los Angeles, Los Angeles, CA, ²Vanderbilt University Medical Center, Franklin, TN, ³Vasculitis Foundation, Chapel Hill, NC, ⁴Vasculitis Foundation, Kansas City, MO, ⁵Health Informatics Institute, Tampa, FL, ⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: To compare the clinical characteristics and determine the reliability of a self-reported diagnosis of giant cell arteritis (GCA) or Takayasu’s arteritis (TAK) from an…
Abstract Number: 0952 • ACR Convergence 2021
Outcomes of COVID-19 Infection in Patients with Primary Systemic Vasculitis and Polymyalgia Rheumatica: Results from the COVID-19 Global Rheumatology Alliance Physician Registry
Sebastian Sattui¹, Richard Conway², Michael Putman³, Andrea Seet⁴, Kaley Beins⁵, Catherine Hill⁶, David Liew⁷, Sarah Mackie⁸, Puja Mehta⁹, Lorna Neill¹⁰, Gimena Gomez¹¹, Maria Salinas¹², Federico Maldonado¹³, Henrique Moriz¹⁴, Samia Studart¹⁵, NAFICE ARAUJO¹⁶, Ann Knight¹⁷, Davide Rozza¹⁸, Luca Quartuccio¹⁹, Maxime Samson²⁰, Stephane Bally²¹, Alexandre Maria²², Pascal Chazerain²³, Rebecca Hasseli²⁴, Ulf Müller-Ladner²⁵, Bimba Franziska Hoyer²⁶, Reinhard Voll²⁷, Rita Pinheiro Torres²⁸, Mariana Luis²⁹, Sandra Lúcia Ribeiro³⁰, Samar Al Emadi³¹, Jeffrey Sparks³², Tiffany Hsu³³, Kristin D'Silva³⁴, Naomi Patel³⁴, Leanna Wise³⁵, Emily Gilbert³⁶, Maria Valenzuela-Almada³⁷, Ali Duarte-Garcia³⁸, Manuel Ugarte-Gil³⁹, Emily Sirotich⁴⁰, Jean Liew⁴¹, Jonathan Hausmann⁴², Paul Sufka⁴³, Suleman Bhana⁴⁴, Rebecca Grainger⁴⁵, Wendy Costello⁴⁶, Lindsay Jacobsohn⁴⁷, Zara Izadi⁴, Anja Strangfeld⁴⁸, Elsa Frazão Mateus⁴⁹, Kimme Hyrich⁵⁰, Laure Gossec⁵¹, Loreto Carmona⁵², Saskia Lawson-Tovey⁵⁰, Lianne Kearsley-Fleet⁵³, Martin Schaefer⁵⁴, Milena Gianfrancesco⁴, Pedro Machado⁵⁵, Zachary Wallace³⁴, Jinoos Yazdany⁴ and Philip Robinson⁵⁶, ¹Hospital for Special Surgery, New York, NY, ²St. James's University Hospital, Dublin, Ireland, ³Medical College of Wisconsin, Brookfield, WI, ⁴University of California San Francisco, San Francisco, CA, ⁵Vasculitis Foundation, Kansas City, MO, ⁶Queen Elizabeth Hospital, Woodville, Australia, ⁷Austin Health, Heidelberg, Australia, ⁸School of Medicine, University of Leeds, Leeds, United Kingdom, ⁹University College London, London, United Kingdom, ¹⁰PMR GCA Scotland, Perth, United Kingdom, ¹¹Research Unit Argentine Society of Rheumatology, Buenos Aires, Argentina, ¹²Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ¹³Sanatorio Güemes, Buenos Aires, Argentina, ¹⁴Hospital das Clinicas, Universidade Federal de Pernambuco, Pernambuco, Brazil, ¹⁵HOSPITAL GERAL DE FORTALEZA, Fortaleza, Brazil, ¹⁶Instituto de ASsistencia Medica ao Servidor Publico Estadual de São Paulo, São Paulo, Brazil, ¹⁷Rheumatology, Institute of Medical Sciences, Uppsala University, Uppsala, Sweden, ¹⁸Epidemiology Research Unit, Italian Society of Rheumatology, Rome, Italy, ¹⁹Clinical Rheumatology, Department of Medicine, University of Udine, Udine, Italy, ²⁰CHU Dijon Bourgogne, Hpital Franois Mitterrand, Dijon, Dijon, France, ²¹Nephrology and Dialysis Service, Metropole Savoie Hospital Center, Chambery, France, ²²Department of Internal Medicine and Multiorganic Diseases, Saint-Eloi University Hospital of Montpellier, Montpellier, France, ²³Department of Rheumatology and Internal Medicine, Diaconesses Croix Saint Simon Hospital, Paris, France, ²⁴Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus Liebig University Giessen, Bad Nauheim, Germany., Bad Nauheim, Germany, ²⁵JLU Giessen, Campus Kerckhoff, Dept. Rheum & Clin Immunol, Bad Nauheim, Germany, ²⁶Universittsklinikum Schleswig-Holstein, Kiel, Germany, ²⁷Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany, ²⁸Rheumatology Service, Egas Moniz Hospital, Lisboa Occidental Hospital Centre, Lisbon, Portugal, ²⁹Department of Rheumatology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portuga, Coimbra, Portugal, ³⁰Universidade Federal do Amazonas, Amazonas, Brazil, ³¹Hamad medical corporation, Doha, Qatar, ³²Brigham and Women's Hospital, Boston, MA, ³³Brigham and Women's Hospital, Jamaica Plain, MA, ³⁴Massachusetts General Hospital, Boston, MA, ³⁵LAC+USC/Keck Medicine of USC, Pasadena, CA, ³⁶Mayo Clinic, Jacksonville, FL, ³⁷Division of Rheumatology, Mayo Clinic, Rochester, MN, ³⁸Mayo Clinic, Rochester, MN, ³⁹Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ⁴⁰McMaster University, Hamilton, ON, Canada, ⁴¹Boston University, Boston, MA, ⁴²Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ⁴³HealthPartners, Eagan, MN, ⁴⁴Crystal Run Health, Montvale, NJ, ⁴⁵University of Otago, Wellington, New Zealand, ⁴⁶Irish Children's Arthritis Network, Bansha, Ireland, ⁴⁷University of California San Francisco, Antioch, CA, ⁴⁸Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁴⁹Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, ⁵⁰University of Manchester, Manchester, United Kingdom, ⁵¹Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ⁵²Instituto de Salud Musculoesqueltica (InMusc), Madrid, Spain, ⁵³Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ⁵⁴German Rheumatism Research Center, Berlin, Germany, ⁵⁵Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ⁵⁶University of Queensland School of Clinical Medicine, Brisbane, Queensland, Australia, Herston, Australia
Background/Purpose: Patients with primary systemic vasculitis (PSV) and polymyalgia rheumatica (PMR) may be at high risk for poor COVID-19 outcomes due to the treatments used,…
Abstract Number: 1409 • ACR Convergence 2021
Clinical Features at Disease Onset of Different Subsets of Large-vessel-giant Cell Arteritis in a Monocentric Cohort of 100 Patients
Francesca Regola¹, Giovanni Bosio², Laura Andreoli³, Franco Franceschini¹ and Paola Toniati¹, ¹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²Nuclear Medicine Unit, ASST Spedali Civili of Brescia, Brescia, Italy, ³University of Brescia, Brescia, Italy
Background/Purpose: Giant Cell Arteritis (GCA) is the most frequent systemic vasculitis in patients older than 50 years involving medium-sized and large arteries. Inflammation of the…
Abstract Number: 1194 • ACR Convergence 2021
A Module on Large Vessel Vasculitis for Learners in Rheumatology
David Shoemaker¹, Stamatina Danielides¹, Abhishek Nandan¹, Huzaefah Syed², Beth Rubinstein¹ and Seema Patel¹, ¹Virginia Commonwealth University, Richmond, VA, ²Virginia Commonwealth University Medical Center, Richmond, VA
Background/Purpose: Of the rheumatic disorders that learners are expected to know, the vasculitides are among the hardest to grasp. Their pathogenesis is not well-established, they…
Abstract Number: 1410 • ACR Convergence 2021
Predictors of Relapse in Giant-Cell Arteritis: A Retrospective Single Center Analysis
Kathleena D'Anna¹, David Lim², Lorena Salto¹ and Mehrnaz Hojjati¹, ¹Loma Linda University Health, Loma Linda, CA, ²Loma Linda University Health, Redlands, CA
Background/Purpose: Giant Cell Arteritis (GCA) is the most common systemic vasculitis in North America, typically affecting Caucasian female adults over 50 years of age. Flares…
Abstract Number: 1394 • ACR Convergence 2021
Vascular Ultrasound for Giant Cell Arteritis: An Effective Diagnostic Modality for a Fast Track Clinic in the United States
Charlie Oshinsky¹, Alison Bays¹, Ingeborg Sacksen², Elizabeth Jernberg³, Eugene zierler¹, Andreas Diamantopoulos⁴ and Scott Pollock¹, ¹University of Washington, Seattle, WA, ²University of Washington, Bellingham, WA, ³Virginia Mason Medical Center, Seattle, WA, ⁴Akerhus University Hospital, Brum, Norway
Background/Purpose: Giant cell arteritis (GCA) is the most common form of large vessel vasculitis. Prompt diagnosis and treatment of GCA is vital to prevent vision…
Abstract Number: 1411 • ACR Convergence 2021
Decreased Use of Ultrasound Fast-track Pathways of Giant Cell Arteritis Due to COVID-19 Pandemic: A Potential Risk for Permanent Visual Loss
Fernando Montero¹, Juan Molina², ISABEL CASTREJON³, Julia Martínez Barrio¹, Juan Carlos Nieto¹ and Jose Maria Alvaro-Gracia¹, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Hospital General Universitario Gregorio Maran, Madrid, Spain, ³Pfizer Spain, Chicago
Background/Purpose: The implementation of ultrasound (US) fast-track pathways (FTP), aiming at an early diagnosis of giant cell arteritis (GCA), has led to a decrease in…
Abstract Number: 1395 • ACR Convergence 2021
Utility and Validity of the Southend Pretest Probability Score (SPTPS) in a Giant Cell Arteritis Fast Track Clinic: Analysis in a Spanish Cohort of 297 Patients
Elisa Fernández-Fernández¹, Irene Monjo² and Eugenio De Miguel³, ¹Rheumatology department, La Paz University Hospital, Madrid, Spain, ²Hospital La Paz - IdiPAZ, Madrid, Spain, ³Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: The implementation of fast track clinics (FTC) has enabled quick diagnosis and reduced the blindness rate of giant cell arteritis (GCA). Recently, the Southend…
Abstract Number: 1412 • ACR Convergence 2021
Effectiveness of Tocilizumab in the Visual Involvement of Giant Cell Arteritis: Multicenter Study of 471 Patients of Clinical Practice
Lara Sánchez-Bilbao¹, Javier Loricera¹, Juan Pablo Valdivieso Achá², Clara Moriano³, Javier Narvaez⁴, Vicente Aldasoro⁵, Olga Maíz⁶, Rafael Melero⁷, Juan Ignacio Villa⁸, Paloma Vela⁹, Susana Romero-Yuste¹⁰, José Luis Callejas¹¹, Eugenio De Miguel¹², Eva Galindez-Agirregoikoa¹³, Francisca Sivera¹⁴, Jesús Carlos Fernández-López¹⁵, Carles Galisteo¹⁶, Iván Ferraz-Amaro¹⁷, Juan Carlos Nieto¹⁸, Juan Ramón de Dios¹⁹, Julio Sánchez²⁰, Esther Fernández²¹, Isabel de la Morena²², Patricia Moya²³, Roser Solans-Laqué²⁴, Jose Luis Andreu²⁵, Marcelino Revenga²⁶, Valvanera Pinillos²⁷, Andrea García-Valle²⁸, Adela Gallego²⁹, Carlota Iñíguez³⁰, Cristina Hidalgo³¹, Noemí Garrido-Puñal³², Ruth López-González³³, José Andrés Román-Ivorra³⁴, Sara Manrique Arija³⁵, Paz Collado³⁶, Enrique Raya¹¹, Francisco Navarro³⁷, Antoni Juan Mas³⁸, Carmen Ordas³⁹, Maria Dolors Boquet⁴⁰, Noelia Álvarez-Rivas⁴¹, Maria Luisa Velloso-Feijoo⁴², Cristina Campos-Fernández⁴³, Íñigo Rúa-Figueroa⁴⁴, Arantxa Conesa⁴⁵, Eva Salgado⁴⁶, Miguel Ángel gonzalez-Gay⁴⁷ and Ricardo Blanco⁴⁸, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario La Princesa, Madrid, Spain, ³Hospital Universitario de León, León, Spain, ⁴Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁵Complejo Hospitalario de Navarra, Pamplona, Spain, ⁶Hospital Universitario de Donostia, San Sebastián, Spain, ⁷Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ⁸Hospital Sierrallana, Torrelavega, Spain, ⁹Hospital General Universitario de Alicante, Alicante, Spain, ¹⁰Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, ¹¹Hospital San Cecilio, Granada, Spain, ¹²Hospital Universitario La Paz, Madrid, Spain, ¹³Hospital Universitario de Basurto, Bilbao, Spain, ¹⁴Hospital Universitario de Elda, Alicante, Spain, ¹⁵Hospital Universitario Juan Canalejo, A Coruña, Spain, ¹⁶Hospital Universitari Parc Tauli, Saadell, Spain, ¹⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹⁸Hospital General Universitario Gregorio Marañón, Madrid, Spain, ¹⁹Hospital Universitario de Araba, Mondragón, Spain, ²⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ²¹Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ²²Hospital Clínico Universitario de Valencia, Valencia, Spain, ²³Hospital Sant Pau, Barcelona, Spain, ²⁴Hospital Vall d'Hebron, Barcelona, Spain, ²⁵Hospital Universitario Puerta de Hierro, Madrid, Spain, ²⁶Hospital Ramón y Cajal, Madrid. Spain., Madrid, Spain, ²⁷Hospital San Pedro, Logroño, Spain, ²⁸Complejo Asistencial Universitario de Palencia, Palencia. Spain, Palencia, Spain, ²⁹Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ³⁰Hospital Universitario Lucus Augusti, Lugo, Galicia, Spain, ³¹Hospital Universitario Salamanca, Salamanca, Spain, ³²Hospital Universitario Virgen del Rocío, Sevilla, Spain, ³³Complejo Hospitalario de Zamora, Zamora, Spain, ³⁴Hospital Universitario y Politécnico La Fe, Valencia, Spain, ³⁵Hospital Regional de Málaga, Málaga. Spain., Malaga, Spain, ³⁶Hospital Universitario Severo Ochoa, Madrid, Spain, ³⁷Hospital General Universitario de Elche, Elche, Spain, ³⁸Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, ³⁹Hospital de Cabueñes, Gijón, Spain, ⁴⁰Hospital Arnau de Vilanova, Lleida. Spain., Lleida, Spain, ⁴¹Hospital San Agustín, Aviles, Spain, ⁴²Hospital Universitario de Valme, Sevilla, Spain, ⁴³Consorci Hospital General Universitari de Valencia, Valencia, Spain, ⁴⁴Hospital Universitario Doctor Negrín, Gran Canaria, Spain, ⁴⁵Hospital Universitario de Castellón, Castellón, Spain, ⁴⁶Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ⁴⁷Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁴⁸Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: One of the most feared complications of giant cell arteritis (GCA) is visual affection. Tocilizumab (TCZ) has demonstrated efficacy and safety in GCA. However,…
Abstract Number: 1396 • ACR Convergence 2021
Baricitinib in Relapsing Giant Cell Arteritis: A Prospective Open-Label Single-Institution Study
Matthew Koster¹, Cynthia Crowson², Rachel Giblon¹, Ali Duarte-Garcia¹, Jane Jaquith¹, Cornelia M. Weyand¹ and Kenneth Warrington³, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN, ³Mayo Clinic, Rochester, Minnesota
Background/Purpose: Pre-clinical giant cell arteritis (GCA) mouse models have demonstrated effective suppression of arterial wall lesional T-cells through inhibition of Janus kinase 3 (JAK3) and…
Abstract Number: 1413 • ACR Convergence 2021
Tocilizumab in Combination with 8 Weeks of Prednisone for Giant Cell Arteritis
Mark Matza¹, Adam Jarvie², Ana Fernandes¹, John Stone³ and Sebastian Unizony⁴, ¹Massachusetts General Hospital, Boston, MA, ²Masssachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital, Winchester, MA
Background/Purpose: Even with the use of tocilizumab (TCZ), significant glucocorticoid exposure (usually ³ 6 months) continues to be an important problem in giant cell arteritis…
Abstract Number: 1397 • ACR Convergence 2021
Treatment of Giant Cell Arteritis with Tocilizumab: A Retrospective Cohort Study of 119 Patients
jigisha rakholiya¹, Matthew Koster¹, Hannah Langenfeld¹, Cynthia Crowson², Andy Abril³, Pankaj Bansal⁴, Lester Mertz⁵, Alicia Rodriguez Pla⁶, Rahul Sehgal⁴, Benjamin Wang⁷ and Kenneth Warrington⁸, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN, ³Mayo Clinic, Ponte Vedra Beach, FL, ⁴Mayo Clinic, Eau Claire, WI, ⁵Mayo Clinic Arizona, Scottsdale, AZ, ⁶Mayo Clinic in Arizona, Scottsdale, AZ, ⁷Mayo Clinic, Jacksonville, FL, ⁸Mayo Clinic, Rochester, Minnesota
Background/Purpose: Giant cell arteritis (GCA) is an inflammatory condition of medium- and large-sized arteries. Prospective clinical trials have demonstrated the efficacy of tocilizumab (TCZ) for…
Abstract Number: 1414 • ACR Convergence 2021
The Current State of Expedited Referral Systems Incorporating Vasculitis Ultrasound for the Diagnosis of Giant Cell Arteritis in Rheumatology Practices in the United States
Mark Matza¹, Karina Torralba² and Minna Kohler³, ¹Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Department of Medicine, Loma Linda University Healthcare, Loma Linda, CA, ³Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Expedited referral systems or “fast-track” clinics incorporating vasculitis ultrasound (VUS) into the evaluation of patients with suspected giant cell arteritis (GCA) have shown reduced…
Abstract Number: 1398 • ACR Convergence 2021
Adrenal Insufficiency After Glucocorticoid Treatment of Giant Cell Arteritis
Alojzija Hocevar¹, Rok Jese¹, Jelka Kramaric², Matija Tomšič³ and Ziga Rotar³, ¹UKC Ljubjana, Ljubjana, Slovenia, ²UKC Ljubjana, Ljubjana, ³Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia
Background/Purpose: Adrenal insufficiency is frequently neglected and underappreciated complication of systemic glucocorticoid therapy. We aimed to evaluate the prevalence of glucocorticoid induced adrenal insufficiency in…
Abstract Number: 1415 • ACR Convergence 2021
Temporal Artery Biopsy Reports Can Be Accurately Classified by Artificial Intelligence
Christopher McMaster¹, Victor Yang¹, Benjamin Sutu², Shereen Oon³, Gene-Siew Ngian³, Ian Wicks³, Russell Buchanan⁴ and David Liew¹, ¹Austin Health, Heidelberg, Australia, ²Melbourne Health, South Yarra, Australia, ³Melbourne Health, Parkville, Australia, ⁴Austin Health, Heidelberg, Melbourne, Australia
Background/Purpose: Studies of giant cell arteritis (GCA) rely on classifying temporal artery biopsies (TABs), the gold-standard diagnostic test. However, these results exist as free text,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].